Craft
  • Home
  •  / Orchard Therapeutics
Orchard Therapeutics

Orchard Therapeutics

Revenue

$1.7 M

FY, 2021

Market Capitalization

$56.8 M

2022-09-20

Orchard Therapeutics Summary

Company summary

Overview
Orchard Therapeutics is a biotechnology company, develops and commercializes transformative ex-vivo autologous hematopoietic stem cell gene therapy to restore normal gene function in primary immune deficiencies, metabolic diseases, and hematological disorders. The сompany also develops adenosine deaminase severe combined immunodeficiency, mucopolysaccharidosis type IIIA, and ex-vivo lentiviral gene therapy programs.
Type
Public
Founded
2015
HQ
London, GB | view all locations
Website
https://www.orchard-tx.com/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Bobby Gaspar

    Bobby Gaspar, Chief Executive Officer, Director

  • John Cerio

    John Cerio, Chief Human Resource Officer

    • Anne Dupraz-Poiseau

      Anne Dupraz-Poiseau, Chief Development Officer

    • John Ilett

      John Ilett, Chief of Staff, Chief Legal Officer, Company Secretary

    LocationsView all

    5 locations detected

    • London, England HQ

      United Kingdom

      108 Cannon St

    • Boston, MA

      United States

      101 Seaport Blvd 7th floor

    • Boston, MA

      United States

      2 Seaport Ln 8th floor

    • Foster City, CA

      United States

      1118 Chess Dr

    • Menlo Park, CA

      United States

      1360 O'Brien Dr

    Orchard Therapeutics Financials

    Summary financials

    Revenue (Q2, 2022)
    $4.4M
    Gross profit (Q2, 2022)
    $3.2M
    Net income (Q2, 2022)
    ($50.9M)
    Cash (Q2, 2022)
    $53.5M
    EBIT (Q2, 2022)
    ($44.7M)
    Enterprise value
    $36.4M

    Footer menu